Biotechnology News 19 December 2025

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences Ltd. (NASDAQ: WVE) is ending 2025 as one of biotech’s most watched “story stocks”—the kind that can go from sleepy to screaming in a single premarket headline, then spend weeks digesting what just happened. On December 24,

24 December 2025

Analyst Forecasts·Biotechnology·Financial Analysis·Investment News·Stock Market

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is having one of those “stock market is a strange animal” moments again: the share price is moving sharply on a story dominated less by traditional fundamentals and more by

24 December 2025

Biotechnology·Financial News·Investment Analysis·Market Forecasts·Stock Market

Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics, Inc. (NASDAQ: INDP) is getting unusual attention heading into December 24, 2025, after a late-December SEC filing laid out a $6.0 million preferred-stock financing, a boardroom reshuffle, and a new co-CEO / chairman appointment—a mix that can ignite

24 December 2025

Biotechnology·Company News·Financial Analysis·Investment Strategies·Stock Market

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed

24 December 2025

Biotechnology·Financial Analysis·Investment News·Pharma Industry·Stock Market

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven

23 December 2025

Biotechnology·Health News·Investment Analysis·Pharmaceuticals·Stock Market

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Inc. (NASDAQ: AMGN) ended Monday, December 22, 2025, modestly higher, but the more important story for Tuesday’s open is what hit after the closing bell: fresh FDA approvals for new denosumab biosimilars that reference Amgen’s blockbuster bone-drug franchises Prolia

23 December 2025

Biotechnology·FDA Approvals·Investment News·Stock Market

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) is ending 2025 with something investors in “tools + genomics” names haven’t always been able to count on: momentum that’s tied to multiple moving pieces—new product launches, partner-driven workflow wins, and a profitability narrative that’s

22 December 2025

Biotechnology·Financial News·Investment Analysis·Market Forecasts·Stock Market

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease

21 December 2025

Biotechnology·FDA Approvals·IPO News·Stock Market

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight heading into December 20, 2025—not because of a single blockbuster headline, but because the stock just posted a sharp, high-volume move that traders and long-term biotech investors both tend to

21 December 2025

Biotechnology·Company Forecasts·Financial News·Investment Analysis·Stock Market

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50

20 December 2025

Biotechnology·Mergers & Acquisitions·Pharmaceutical Industry·Stock Market

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) is back in the spotlight on Friday, December 19, 2025, as investors weigh a fresh set of operational updates, capital-return signals, and Wall Street forecasts. Shares were trading around $569.54, up about 1.27% on

19 December 2025

Analyst Forecasts·Biotechnology·Financial News·Investing·Stock Market

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

December 19, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight after a sharp one-day rebound that followed a volatile stretch for the clinical-stage biotech. EWTX closed Dec. 19, 2025 at $23.01, up +8.79% on the day

19 December 2025

Biotechnology·Company News·Financial Forecasts·Investment Analysis·Stock Market

Biotechnology News 19 December 2025 - 24 December 2025